Characteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:1973-2015 Amanda Kahl, MPH Mary E. Charlton, PhD, Imran Hassan, MD, Paolo Goffredo, MD, Catherine Chioreso, MPH, & Chi Lin, MD Oral Presentation, NAACCR June 14, 2018
29
Embed
Characteristics, treatment patterns, and survival outcomes ... · Esophagus Stomach Small intestine Colon Rectum Anus. Background 60% of metastatic skin melanomas have GI involvement
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Characteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:1973-2015
Amanda Kahl, MPH Mary E. Charlton, PhD, Imran Hassan, MD, Paolo Goffredo, MD,
Catherine Chioreso, MPH, & Chi Lin, MD Oral Presentation, NAACCR
June 14, 2018
Background
▪Melanoma: ~10% of all primary cancer diagnoses in US ▪5th and 6th most common cancer in males and females
▪Rare cases of primary gastrointestinal (GI) melanoma ▪Reported to arise from mucosal membranes of the ▪Esophagus ▪Stomach ▪Small intestine ▪Colon ▪Rectum ▪Anus
Background
▪60% of metastatic skin melanomas have GI involvement at autopsy
▪HOWEVER, several studies reported GI melanoma in the absence of skin melanoma → But HOW?? ▪Stem cells differentiating into melanocytes in the GI tract ▪Cell migration
Primary GI Melanoma
▪Most studies of GI melanoma have been based on case series ▪Population-based cancer registries allow for examination of rare cancers over long periods of time
Study objective
▪Compare characteristics, treatment, and survival between skin melanoma and primary GI melanoma ▪Including sites of the esophagus, stomach, small intestine, colon, rectum, and anus
First primary malignant melanoma: - GI melanoma N=828
- Skin melanoma N=304,797
Not reported via autopsy or
death certificate - GI melanoma N=827
- Skin melanoma N=304,082
Excluded:
GI melanoma N=1
Skin melanoma N=715
Ages 18-100
- GI melanoma N=827
- Skin melanoma N=302,194
Excluded:
GI melanoma N=0
Skin melanoma N=1,888
Methods
▪SEER*Stat used to extract patient, tumor and treatment variables ▪Statistical analysis performed in SAS ▪Chi-square tests for bivariate analyses ▪Cause-specific Survival Cox proportional hazard models
▪Incidence rates (1973-2015) were calculated in SEER*Stat and analyzed in Joinpoint
Results
GI Melanoma Incidence Rate, SEER 18 1973-2015
Patient characteristics between GI melanoma and skin melanoma,1973-2015
Cutaneous Melanoma GI Melanoma (N=302,194) (N=827) N % N % p-valueAge at diagnosis 18-49 98,994 33% 95 12% <0.0001 50-69 125,842 42% 327 40% 70-100 77,358 26% 405 49% Sex Female 135,090 45% 483 58% <0.0001 Male 167,104 55% 344 42% Race White 285,387 94% 695 84% <0.0001 Non-White 16,807 6% 132 16% Married Yes 156,993 52% 434 53% 0.762 No 145,201 48% 393 48% Year of diagnosis 1973-1987 26,754 9% 68 8% 0.973 1988-1994 23,102 8% 62 8% 1995-2001 47,936 16% 130 16% 2002-2008 93,313 31% 259 31% 2009-2015 111,089 37% 308 37%
Skin Melanoma vs GI Melanoma
Tumorcharacteristics between patients with GI melanoma and skin melanoma,1973-2015
No/Unknown 508 80% 100 80% *Due to the large number of unknown surgery for cases diagnosed prior to 1988, they were excluded from the treatment variables
Anorectal vs Other GI site Melanoma
Kaplan Meier Cause-Specific Survival Curves
Survival of GI melanoma and skin melanoma patients,1973-2015
Survival of localized GI melanoma and skin melanoma patients,1973-2015
Localized
Survival of regional GI melanoma and skin melanoma patients,1973-2015
Regional
Survival of distantGI melanoma and skin melanoma patients,1973-2015
Distant
Cause-Specific Survival (CSS) Hazard Models
CSS adjusted hazard model including both GI melanoma and skin melanoma 1988-2015 (N=228,927)*Surgery NOS or Unknown Surgery; Unstaged, and Unknown size were excluded from model
All cases HR 95% CICancer Type Cutaneous Melanoma 0.29 (0.25, 0.33) Anorectal Melanoma 1.00 REF
Other GI site Melanoma 0.58 (0.42, 0.81)
Age at diagnosis 18-49 0.37 (0.35, 0.38) 50-69 0.55 (0.53, 0.56) 70-100 1.00 REFSex Female 0.67 (0.65, 0.69) Male 1.00 REFRace White 1.00 REF Non-White 0.74 (0.68, 0.80)Married Yes 1.00 REF No 1.08 (1.05, 1.11)Year of diagnosis 1988-1994 1.00 REF 1995-2001 0.85 (0.80, 0.89) 2002-2008 0.82 (0.78, 0.87) 2009-2015 0.76 (0.71, 0.81)SEER Summary Stage Localized 1.00 REF
Regional 7.05 (6.84, 7.27)
CSS adjusted hazard model including both GI melanoma and skin melanoma 1988-2015 (N=228,927)*Surgery NOS or Unknown Surgery; Unstaged, and Unknown size were excluded from model
All cases HR 95% CISurgery Local tumor excision 1.00 REF Major resection 1.37 (1.30, 1.44)
None or local tumor destruction only 1.54 (1.41, 1.68)
CSS adjusted hazard model of GI melanoma 1988-2015 (N=440) *Surgery NOS or Unknown Surgery; Unstaged, and Unknown size were excluded from model
GI Melanoma HR 95% CI Cancer Type Anorectal Melanoma 1.00 REF
Other GI site Melanoma 0.92 (0.63, 1.34)
Age at diagnosis 18-49 0.56 (0.38, 0.84) 50-69 0.88 (0.67, 1.15) 70-100 1.00 REFSex Female 1.02 (0.80, 1.32) Male 1.00 REFRace White 1.00 REF Non-White 1.12 (0.82, 1.53)Married Yes 1.00 REF No 0.82 (0.65, 1.05)Year of diagnosis 1988-1994 1.00 REF 1995-2001 0.98 (0.59, 1.62) 2002-2008 0.82 (0.51, 1.32) 2009-2015 0.72 (0.44, 1.16)SEER Summary Stage Localized 1.00 REF
Regional 1.73 (1.24, 2.40)
CSS adjusted hazard model of GI melanoma 1988-2015 (N=440)*Surgery NOS or Unknown Surgery; Unstaged, and Unknown size were excluded from model
GI Melanoma HR 95% CITumor Size <2 cm 1.00 REF 2-<5 cm 1.13 (0.80, 1.61) >=5 cm 1.07 (0.72, 1.59)Surgery Local tumor excision 1.00 REF Major resection 0.92 (0.67, 1.27)
None or local tumor destruction only 1.62 (1.04, 2.51)
▪Incidence of GI melanoma has increased over time ▪Skin melanoma has better prognosis overall and at every stage compared to GI melanoma ▪Local tumor excision is no better than major resection for GI melanoma
Limitations & Strengths
Limitations
▪Small number of GI melanomas in individual sites
▪Cases with GI melanoma may have undiagnosed primary skin melanoma
▪Chemotherapy and radiation variables have sensitivity of 68% and 80%, respectively
Strengths
▪ SEER data provide detailed information about cancer stage and treatment at time of diagnosis
▪One of the first population based studies that characterizes the epidemiology, treatment, and survival of primary GI melanoma that includes sites of the esophagus, stomach, small intestine, colon, rectum, and anus compared to skin melanoma.